---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034689"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:12:13.910603+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025

## Summary
- Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.
- FY2024 net loss $15.0M ($87.68/share) vs $0.1M ($8.44/share) in FY2023.
- Cash and equivalents $6.5M at Dec 31, 2024, down from $12.0M a year ago.
- Operating cash burn $18.3M in FY2024 vs $7.3M in FY2023.
- Phase 1b PRIME study of Gemini in CKD patients dosing; topline data expected mid-2025.

## SEC filing metadata
- accession: 0000950170-25-034689
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/0000950170-25-034689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/revb-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034689
- JSON: https://secwatch.observer/filing/0000950170-25-034689.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.